Steamboat Springs, CO, United States of America

Heinrich Röder

USPTO Granted Patents = 40 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 16)

Average Co-Inventor Count = 3.2

ph-index = 11

Forward Citations = 302(Granted Patents)

Company Filing History:

University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12230398 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2025-02-18),

2. 12094587 - Apparatus and method for identification of primary immune resistance in cancer patients (2024-09-17),

3. 11894147 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2024-02-06),

4. 11710539 - Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy (2023-07-25),

5. 11621057 - Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy (2023-04-04),

6. 11594403 - Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample (2023-02-28),

7. 11476003 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2022-10-18),

8. 11150238 - Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups (2021-10-19),

9. 10950348 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2021-03-16),

10. 10713590 - Bagged filtering method for selection and deselection of features for classification (2020-07-14),

11. 10593529 - Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies (2020-03-17),

12. 10489550 - Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample (2019-11-26),

13. 10217620 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2019-02-26),

14. 10037874 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2018-07-31),

15. 10007766 - Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2018-06-26),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide assistance with the request to write an article about inventor Heinrich Röder.

Title: Heinrich Röder: Pioneering Innovator Shaping Future Technologies

Introduction:

Heinrich Röder, a visionary inventor based in Steamboat Springs, CO (US), is renowned for his passion for innovation and his unwavering commitment to excellence. With a impressive portfolio of 37 patents, Röder continues to inspire the next generation of inventors and significantly influence the future of technology.

Latest Patents:

1. Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization: Röder's innovative method involves utilizing electronic health record attributes to predict unfavorable outcomes for patients admitted to hospitals with COVID-19 infections. The method employs a hierarchical classifier to assess risks and guide patient care effectively.

2. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy: Röder's method utilizes mass spectrometry data to predict the likelihood of melanoma patients benefiting from high dose IL2 therapy. This groundbreaking approach enhances treatment decision-making by analyzing blood-based samples and reference data sets.

Career Highlights:

Röder has made significant contributions while working with esteemed companies such as Biodesix, Inc. and Globeimmune, Inc. His innovative solutions have not only revolutionized healthcare practices but have also led to advancements in personalized medicine and patient care.

Collaborations:

Throughout his career, Röder has collaborated with talented individuals like Joanna Röder and Julia Grigorieva. These partnerships have fueled innovation, fostered creativity, and paved the way for groundbreaking developments in the field of healthcare technology.

Conclusion:

Heinrich Röder's relentless pursuit of innovation, coupled with his dedication to excellence, underscores his status as a pioneering inventor shaping the landscape of future technologies. His inventive spirit serves as a beacon of inspiration for aspiring inventors and underscores the transformative power of innovation in driving positive change in society.

This text is generated by artificial intelligence and may not be accurate.